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Comprehensive mutational analysis of primary and relapse
acute promyelocytic leukemia
V Madan1, P Shyamsunder1,23, L Han1,2,23, A Mayakonda1,23, Y Nagata3, J Sundaresan1, D Kanojia1, K Yoshida3, S Ganesan4, N Hattori1,
N Fulton5, K-T Tan1, T Alpermann6, M-C Kuo7, S Rostami8, J Matthews9, M Sanada3, L-Z Liu1, Y Shiraishi10, S Miyano10, E Chendamarai4,
H-A Hou11, G Malnassy5, T Ma12, M Garg1, L-W Ding1, Q-Y Sun1, W Chien1, T Ikezoe13, M Lill14, A Biondi15, RA Larson16, BL Powell17,
M Lübbert12, WJ Chng1,2,18, H-F Tien11, M Heuser19, A Ganser19, M Koren-Michowitz20,21, SM Kornblau9, HM Kantarjian9, D Nowak22,
W-K Hofmann22, H Yang1, W Stock5, A Ghavamzadeh8, K Alimoghaddam8, T Haferlach6, S Ogawa3, L-Y Shih7, V Mathews4,24
and HP Koeffler1,14,18,24
Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte
stage. Besides the presence of chromosomal rearrangement t(15;17), leading to the formation of PML-RARA (promyelocytic
leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed
comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in
the pathogenesis of APL. We explored the mutational landscape using whole-exome (n= 12) and subsequent targeted sequencing
of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic
mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas
mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse
was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence
of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of
the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression
and reduced in vitro differentiation potential.
Leukemia (2016) 30, 1672–1681; doi:10.1038/leu.2016.69
INTRODUCTION
Acute promyelocytic leukemia (APL) is a distinct subtype of
myeloid leukemia characterized by differentiation block resulting
in accumulation of leukemic promyelocytes in the bone marrow.
The disease is defined by a single genetic alteration involving
chromosomal translocation 15;17, leading to the formation of
oncogenic fusion protein PML-RARA (promyelocytic leukemia-
retinoic acid receptor alpha).1–3 A minority of APL cases (o5%)
harbor fusion of RARA gene with other partners including PLZF,
NPM1, NUMA1 and STAT5B.4,5 Although the translocations invol-
ving RARA are a constant event in APL, additional genetic events
have been identified, including somatic alterations of FLT3 and
NRAS genes.6,7 Moreover, expression of PML-RARA in mice is
associated with long latency of onset of disease and variable
penetrance.8–11 This suggests that secondary genetic abnormalities
contribute to the pathogenesis of APL. Sequencing of a mouse APL
genome revealed recurrent mutations in Jak1 and deletions
comprising Kdm6a gene.12 Previous next-generation sequencing
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studies, which have aimed to identify cooperating mutations in
APL, were limited by either small sample size13,14 or focus on newly
diagnosed APL.7
Targeted therapy with all-trans retinoic acid (ATRA) and arsenic
trioxide (ATO) have revolutionized the treatment of APL in the
past three decades.15,16 Recent advances have included high
efficacy of ATO as a frontline agent in newly diagnosed APL17–20
and high rates of cure and shorter time to remission observed
with the combination of ATRA and ATO.21,22 Both ATRA and ATO
target PML-RARA fusion protein and trigger its degradation by
non-overlapping mechanisms, leading to restoration of normal
retinoid signaling.15,23 Despite the remarkable improvement in the
treatment outcome in APL, a number of resistance-related
treatment failures and relapses are observed in both ATRA- and
ATO-treated APL.17–20,24–26 Somatic mutations of RARA and PML
genes associated with treatment resistance have been reported in
APL relapse.27–32 However, landscape of genetic aberrations
acquired at relapse following these two discrete treatment
regimens has not been systematically examined.
In this study, whole-exome and targeted exome sequencing of
a large APL cohort was used to uncover mutational spectrum both
at initial diagnosis and relapse. Samples from 212 APL cases
(comprising 30 primary/relapse pair) including relapses arising
subsequent to either ATRA or ATO treatment were analyzed.
A mutational signature distinctive from other myeloid leukemias
was identified and recurrent mutations of SWI/SNF members
ARID1A and ARID1B were discovered. Sequencing data demon-
strated that APL relapse is characterized by acquisition of frequent
alterations in PML and RARA genes, specifically in ATO- and ATRA-
treated cases, respectively. Our experiments also demonstrate that
silencing of ARID1B leads to impaired differentiation of NB4 cells
in response to ATRA.
MATERIALS AND METHODS
Sample collection and genomic DNA extraction
Genomic DNA or frozen cell pellets from disease/remission stages were
obtained from various institutes and hospitals. Informed consent was
obtained in accordance with the Declaration of Helsinki and approved by
the Institutional Review Board of respective institutes. Genomic DNA was
extracted from cell pellets using DNeasy Blood and Tissue Kit (Qiagen,
Valencia, CA, USA). DNA was quantified using Qubit Fluorometer (Life
Technologies, Carlsbad, CA, USA) and DNA integrity was assessed by
agarose gel electrophoresis. DNA was amplified using REPLI-g UltraFast
Mini Kit (Qiagen) for samples with insufficient quantity. DNA was sheared
using Covaris instrument (Woburn, MA, USA) and assessed on 2100
Bioanalyzer (Agilent, Santa Clara, CA, USA) before library preparation.
Whole-exome and targeted capture sequencing
For whole-exome sequencing, DNA libraries were prepared using
SureSelect Human All Exon (50 Mb) Kit (Agilent), as per the manufacturer’s
instructions. For targeted capture library, customized RNA baits were
designed to capture exons of 398 genes. Libraries were prepared using
SureSelect XT2 Target Enrichment System (Agilent) for Illumina Multi-
plexed Sequencing and sequenced on HiSeq 2000 platform (Illumina,
San Diego, CA, USA).
Somatic variant discovery and validation
Paired-end reads of 100 bp were aligned to hg19 reference genome using
bwa mem (http://arxiv.org/abs/1303.3997v2) in default mode. Duplicates were
marked with Samblaster.33 Resulting bam files were further processed
according to Genome Analysis Toolkit (GATK) best practices (https://www.
broadinstitute.org/gatk/guide/bp_step.php?p=1), by performing Indel Rea-
lignment and Base Quality Recalibration. Minimummapping quality of 15 was
considered for variant calling. Somatic variants were called using two
methods: ebCall34 and VarScan2 (version 2.3.8).35 Mutations supported by
either o5 reads or those supported by reads in only one direction were
excluded. Also, variants with variant allele frequencies o0.05 were
disregarded. Processed somatic variants were later filtered for false positives
using varscan2 fpfilter command. Final confident variants were annotated
using annovar and oncotator. Commonly found SNPs in general population
were filtered out using dbSNP135, 1000 Genomes and our in-house SNP
databases, while retaining the clinically associated variants. For samples
without germline samples, we retained variants that passed the criteria
outlined in Supplementary Figure S1. Oncoplots were drawn using mafTools
(https://github.com/PoisonAlien/mafTools) and ComplexHeatmap bioconduc-
tor package. Clonality analysis was carried out using sciClone.36 Mutual
exclusion relationships between frequently mutated genes were assessed by
Mutation-Relation Test.37 All somatic mutations reported in this study were
validated by Sanger sequencing. The sequencing data have been deposited in
the NCBI Sequence Read Archive under accession code SRP070515.
Generation of ARID1B knockdown cell lines
Short hairpin (sh) RNA sequences were cloned into AgeI/EcoRI sites of
pLKO.1 lentiviral vector (Sigma, St Louis, MO, USA) and viral particles were
generated by transfection in 293T cells, as described previously.38 Viral
supernatant was collected 48 and 72 h after transfection, and used to
transduce NB4 cells (provided by Dr Wee Joo Chng, Singapore) two times,
24 h apart. Cells were selected in puromycin to generate stably knockdown
cell lines. The target sequence for human ARID1B sh2 and sh3 are
5′-GCAGGACATGTACAACCAAAG-3′ and 5′-GCCGAATTACAAACGCCATAT
-3′, respectively.
RESULTS
Analysis of APL exomes at diagnosis and relapse
Whole-exome sequencing was used to characterize the genetic
alterations in 12 primary diagnosis APL with eight matched
relapse samples (Table 1 and Supplementary Table S1). Complete
remission samples that were negative for PML-RARA fusion allele
were used as germline control. We achieved a mean depth of 117x
(range 79–159x) and an average 81% of nucleotides were covered
by at least 20 reads (Supplementary Figure S2). We validated a
total of 115 somatic non-silent mutations in 109 genes using
Sanger sequencing (Supplementary Table S2). We observed that
the average number of nonsynonymous and synonymous
mutations at relapse remained unchanged compared with the
initial diagnosis (two-tailed Student's t-test) (Figure 1a). Recurrent
Table 1. Dx and Rel APL samples sequenced in this study
Number of samples
Dx 165 (147)
Rel 77 (40)
Total 242 (187)
Paired Dx
+Rel
Unpaired
Dx
Unpaired
Rel
Sample specifics
Discovery cohort (whole exome) 8 (8) 4 (4) 0
Frequency cohort (targeted exome) 22 (14) 131 (121) 47 (18)
Total 30 (22) 135 (125) 47 (18)
Relapse (prior therapy at Dx)
ATRA 33
ATO 41
Information unavailable 3
Age (at diagnosis)
Median 37 years
Range 4-69 years
Gender
Male 56.7%
Female 43.3%
Abbreviations: APL, acute promyelocytic leukemia; Dx, newly diagnosed;
Rel, relapse. Numbers within parentheses represent the number of samples
with matched germline control.
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mutations were observed in FLT3, WT1 and PML genes, with
mutations of PML detected only in relapse samples. Mutations in
other novel genes such as ARID1A, CEBPE, AKT1, KAT6A and HK3
were also detected in one sample each (Supplementary Table S2
and Supplementary Figure S3). Among the eight diagnosis–
relapse pairs, six samples had mutations that were shared
between the two disease stages, indicating re-emergence of
disease subclone following therapy (Supplementary Figure S3).
Although, no non-silent mutation common to both diagnosis and
relapse was detected in DS1 and DS6, PML-RARA fusion was the
common genetic lesion, indicating that the relapse evolved from
an ancestral clone (Figure 1b and Supplementary Figure S3).
Although sequencing depth was inadequate to discover minor
subclones, clustering analysis outlined an evolutionary pattern
where the founding clone or a subclone at primary disease
acquired additional lesions at relapse (number of variants in DS11
were insufficient for clustering) (Figure 1b), similar to as previously
described for acute myeloid leukemia (AML).39–41
Mutational topography of primary APL
Next, to uncover the repertoire of somatic mutations in APL,
targeted sequencing was performed on exons of 398 genes,
including 109 genes identified in our discovery cohort. The
additional genes (listed in Supplementary Table S3) comprised
those either previously implicated in hematological malignancies
or identified in earlier leukemia sequencing studies. In this
frequency cohort, we sequenced 22 paired diagnosis and relapse
samples. In addition, 131 unpaired newly diagnosed and 47
unpaired relapse samples, making a total of 200 individual APL
samples, were also sequenced (Supplementary Table S4). The
number of samples analyzed in this study is summarized in
Table 1. The mean sequencing depth was 272x (range 40–865x),
with 90% of target bases covered 420x (Supplementary
Figure S4). C–T transition was the most frequent nucleotide
substitution at both primary and relapse APL (Supplementary
Figure S5).
To identify significantly mutated genes in APL, we excluded
from further analysis several genes (listed in Supplementary Table
S5) that frequently exhibit high rate of variants because of large
size and constitute potential false positives in cancer sequencing
studies.42,43 Somatic variants identified in bioinformatics analysis
were verified using Sanger sequencing. Overall, 210 non-silent
point mutations and small insertions/deletions were validated in
our frequency cohort. In addition, the presence of FLT3-ITD (fms-
like tyrosine kinase 3-internal tandem duplication) was examined
using the Genomon ITDetector44 and verified using PCR analysis.
Our collective analysis of discovery and frequency cohorts
revealed FLT3 as most frequently altered gene in primary APL
(Figure 2), similar to observation in an earlier study.7 This included
27% cases with FLT3-ITD (45 out of 165 initial diagnosis samples)
and 16% cases (26 mutations in 25 samples) with point mutations
of FLT3 (Figure 2 and Supplementary Tables S1). In fact, alteration
of FLT3 gene was a sole genetic aberration present in 25% of
newly diagnosed APL cases (39/153 in frequency cohort),
signifying their cooperativity with PML-RARA fusion in driving
the disease. The somatic mutations of FLT3 predominantly
occurred in the tyrosine kinase domains 1 and 2 and in the
juxtamembrane domain, with D835 residue most frequently
mutated (18/27 cases) (Supplementary Figure S6 and
Supplementary Tables S2 and S6). Other known AML genes that
were recurrently mutated in our cohort included WT1 (14%), NRAS
(10%), KRAS (4%), ETV6 (1%) and EZH2 (1%) (Figure 2). Mutations of
NRAS gene clustered at amino-acid residues G12, G13 and V14,
whereas KRAS mutations occurred at G12 and Q61 residues
(Supplementary Figure S6 and Supplementary Table S6). In
addition, missense mutations at K117 and A146 were also
detected in KRAS. Majority of WT1 mutations resulted in truncated
protein (seven nonsense, seven frameshift insertions/deletions
and one splice site mutation out of 23 mutations). In addition,
eight missense substitutions were clustered in the C-terminus
region encoding Zn-finger domains (Supplementary Figure S6).
Our sequencing analysis also revealed the absence of FLT3-ITD or
non-silent mutation in any known driver genes in a quarter of
primary APL samples (27%; 43/153 frequency cohort), suggesting
that a single detectable genetic lesion (PML-RARA fusion) was
sufficient to drive the disease.
Mutation-relation test37 was used to examine the association
between mutations identified in primary APL. FLT3-ITD rarely co-
occurred with mutations in FLT3 or WT1 genes (Po0.01). Similarly,
mutations of Ras pathway genes (NRAS and KRAS) were
predominantly detected in cases with wild-type FLT3 (FLT3-ITD
vs NRAS mutation, P= 0.022; FLT3-ITD vs KRAS mutation, P= 0.024;
FLT3 mutation vs NRAS mutation, P= 0.027).
APL exhibits distinct mutational signature among myeloid
leukemia
Sequencing of a large cohort enabled us to contrast the
mutational pattern of APL to other AML subtypes. Mutational
frequencies of recurrently mutated genes in newly diagnosed APL
Figure 1. Characteristics of somatic mutations detected at primary and relapse APL. (a) Comparison of mutational load between primary and
relapse APL. Boxplots depict median and range for numbers of nonsynonymous and synonymous variants identified per exome. Difference
between average number of variants between two groups was estimated using two-tailed Student's t-test. (b) Clustering analysis using variant
allele frequencies (VAFs) of all somatic variants (VAF ⩾ 0.08) observed at primary and relapse APL. DS2 and DS6 are shown as two
representative cases, which harbor common or exclusive somatic mutations, respectively, at initial diagnosis and relapse.
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were compared with non-M3 AML samples in TCGA data set.
Somatic mutations in known leukemia-related genes (e.g.
DNMT3A, NPM1, TET2, IDH1, IDH2 and ASXL1) were absent or
rarely observed in APL (Figure 3a). This was evident not only in the
primary disease, as previously noted by Welch et al.,7 but also at
relapse (two cases with mutation of TET2; one case with mutations
of DNMT3A; no mutation of NPM1, ASXL1, IDH1 and IDH2 genes
were observed in our study) (Supplementary Table S6). An
increased incidence of FLT3 alterations occurred in APL compared
with other AML subtypes, although the difference did not reach
statistical significance (FLT3-ITD: 27.3% in APL vs 18.9% in other
AML, P= 0.191; mutant FLT3: 15.8% in APL vs 9.7% in other AML,
P=0.078) (Supplementary Figure S7). On the other hand, mutational
frequency of other known drivers such as NRAS, KRAS, EZH2 and
ETV6 were comparable between primary APL and other AML
(Supplementary Figure S7). Our sequencing data also revealed
recurrent mutations in several genes either previously unidentified
in APL or mutated at higher frequency compared with other AML
subtypes. These included two members of the SWI/SNF complex,
ARID1B and ARID1A (Fisher's exact test, Po0.05), both of
which exhibited high proportion of loss-of-function alterations
including frameshift insertions/deletions or nonsense mutations
(Figures 3a–c). We also noted recurrent mutations of other lesser
recognized genes such as CEBPE, NUMA1, RUNX1T1, HUWE1, HK3
and USP9X. These observations highlight a distinctive mutational
profile for APL, distinguishing it from other AML subtypes.
Landscape of somatic mutations at APL relapse
To obtain insights into mutations either specifically present or
enriched in APL relapse, mutational frequencies at initial diagnosis
and relapse (morphological relapses) were compared. Signifi-
cantly, higher frequency of mutations in four genes were detected
in relapse samples, including PML, RARA, RUNX1 and ARID1B
(Fisher’s exact test; Po0.05) (Figure 4a). FLT3-ITD was the most
frequent lesion at relapse, at a frequency similar to that observed
at primary APL. On the other hand, mutations of FLT3 were
enriched in the primary APL samples and their incidence in
relapse samples was significantly reduced (15.8% in diagnosis vs
5.2% in relapse; Fisher’s exact test; Po0.05) (Figures 2 and 4a).
Similar to the pattern observed in FLT3, mutations of both NRAS
and KRAS occurred at a higher frequency in newly diagnosed
samples compared with the relapse, albeit the difference in their
mutational frequencies between the two stages did not reach
statistical significance (NRAS: 9.7% in newly diagnosed and 5.2% in
relapse; KRAS: 3.6% in primary APL and 1.3% in relapse). On the
other hand, mutational frequency of WT1 did not vary significantly
between diagnosis and relapse stages (13.9% in primary APL and
18.2% in relapse).
Missense mutations of RARA were detected in seven relapse
cases (eight mutations), all of which harbored mutations in the
ligand-binding domain. One sample (222 R) had a second
mutation of RARA (R217P) present in the vicinity of ligand-
binding domain (Figure 4b). Three samples (four mutations),
where RNA was available, showed that all four mutations of RARA
were present in the PML-RARA fusion allele (Supplementary
Figure S8). Similar mutations affecting the ligand-binding domain
of RARA in the PML-RARA allele have also been reported
previously.28,45 Thirteen mutations of PML (in 11 cases) were
observed in relapse APL, of which 12 were clustered in the B2
domain, and A216V was the most frequent alteration (Figure 4c).
Although mutations in close proximity of C212-C213 dicysteine
residues, which are involved in binding to PML, have been
described, a missense mutation at N191 in B2 domain was also
identified. A frameshift deletion in a shorter PML isoform
(NM_033249; S482) was also detected in relapse APL. In addition,
a newly diagnosed case harbored a missense mutation at E699 (its
matched relapse sample was not available). One relapse case
(249 R) harbored two mutations (a missense and a nonsense point
mutation) at the C213 residue, indicating that both PML alleles
Figure 2. Recurrently mutated genes in primary APL. Mutational topography of newly diagnosed APL is depicted. Top 20 mutated genes
validated by Sanger sequencing are shown and are color-coded for various types of mutation. Genes are displayed according to decreasing
mutational frequency from top to bottom. Samples are displayed as columns and arranged to emphasize mutual exclusivity. Samples in which
either no driver mutation was detected in our analysis pipeline or do not harbor mutations of top 20 genes are not included in the matrix. Bars
on the right side depict absolute number of mutations in each gene.
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were affected. RNA was available for three cases, of which two
cases harbored mutations in the PML-RARA allele (Supplementary
Figure S9). However, one case had mutations of D219-S220
dinucleotide in the wild-type PML allele (Supplementary Figure S9),
indicating that disruption of normal PML function may have
implications in APL.
We categorized our relapse samples into two groups, based on
the treatment approach used at the primary disease, which was
either ATRA (with or without chemotherapy) or arsenic trioxide
(Table 1). Using this classification, a divergence was observed in
the mutational pattern of PML and RARA genes in relapse
following ATO and ATRA therapy, respectively. While 12 of 13
PML mutations (10/11 cases) occurred in post-ATO relapse, RARA
mutations were more frequent post-ATRA treatment (6/8 muta-
tions of RARA were detected post-ATRA treatment) (in 5 of 7
cases). Interestingly, one relapse sample (245 R; post-ATO relapse)
had mutations of both PML and RARA genes (Supplementary
Tables S4 and S6).
Although RUNX1 mutations were rare in newly diagnosed APL,
they occurred at a higher frequency at relapse (0.6% at primary
APL and 6.5% at relapse) (Figure 4d). Interestingly, five of the six
mutations of RUNX1 were either frameshift insertion/deletions or
nonsense mutations (Supplementary Table S6). Notably, we
observed that mutations in ARID1B were also significantly
enriched at relapse (3.0% at initial diagnosis and 11.7% at
relapse), whereas ARID1A was mutated at a similar frequency
at both stages of disease (4.8% at initial diagnosis and 5.2% at
relapse). Both genes predominantly exhibited loss-of-function
mutations, and two cases (159D and 210 R) harbored frameshift
insertions of both ARID1A and ARID1B (Supplementary Table S6).
Figure 3. Distinct mutational profile of newly diagnosed APL. (a) Bars represent mutational rates of genes mutated at significantly different
frequencies (Fisher’s exact test; Po0.05) between APL and other AML subtypes at initial diagnosis. Frequency of validated non-silent
mutations in 165 newly diagnosed APL samples analyzed in this study was compared with 176 non-APL AML samples from the TCGA
database. TTN, which is most frequently mutated in public exomes,42 and MT-CYB, which was not included in our targeted sequencing, were
excluded from this representation. (b and c) Schematic representation of protein domains of ARID1A (b) and ARID1B (c) was drawn with DOG
2.0 software (http://dog.biocuckoo.org) using domain information from NCBI Protein database (http://www.ncbi.nlm.nih.gov/protein).
Location and type of all somatic mutations verified at primary and relapse APL are shown. Circles depicting individual mutations are color-
coded for different types of mutations.
Mutational profile of primary and relapse APL
V Madan et al
1676
Leukemia (2016) 1672 – 1681 © 2016 Macmillan Publishers Limited
Moreover, three cases with ARID1B mutations also harbored PML
mutations, indicating cooperativity between the two genes
(Figure 4a).
Knockdown of ARID1B leads to impaired differentiation of
NB4 cells
Next, we investigated the functional consequences of the loss of
ARID1B, one of the novel mutated gene in APL, on growth and
differentiation of APL cells. To replicate the deficiency of ARID1B
caused by truncating lesions, we used shRNA-mediated gene
knockdown approach to stably downregulate expression of
ARID1B in NB4 cells. Two shRNA sequences (sh2 and sh3)
significantly silenced the expression of ARID1B at both the
transcript and protein levels (Figures 5a and b), without affecting
the expression of ARID1A, a closely related member of ARID1
family (Supplementary Figure S10). Suppression of ARID1B did
not significantly alter the growth of NB4 cells in liquid culture
over 4 days (Supplementary Figure S11). In the colony-forming
assay, ARID1B knockdown cells exhibited a moderate increase in
the number of colonies observed after 9 days (Figure 5c).
NB4 cells can undergo granulocytic differentiation upon ATRA
Figure 4. Spectrum of somatic mutations at APL relapse. (a) Matrix displays top 15 genes recurrently mutated at relapsed APL. Each column
represents a relapse sample. Genes are arranged according to decreasing mutational frequencies from top to bottom. Right panel illustrates the
number of mutations for all genes. Only those relapse samples that harbor mutations of top 15 genes are included in the matrix. (b–d) Protein
domains for RARA (b), PML (c) and RUNX1 (d) are drawn using the DOG 2.0 software (http://dog.biocuckoo.org), and type and location of validated
mutations are illustrated. Information about protein domains was obtained from Human Protein Reference Database (http://www.hprd.org). All
except one missense mutation (E699K) of PML were found in relapse samples. One frameshift deletion in PML transcript NM_033249 (NP_15025;
S482fs) is not shown. All mutations of RARA were detected in relapse. Only one of the six mutations of RARA occurred in newly diagnosed samples.
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treatment, and we used this in vitro model to assess the
differentiation of ARID1B-deficient cells. We noticed that knock-
down of ARID1B resulted in a small increase in CD11b expression
compared with control shRNA-transduced cells without stimula-
tion with ATRA (Supplementary Figure S12). Treatment of cells
with different concentrations of ATRA-induced expression of
CD11b in a dose- and time-dependent manner. However,
increase in the proportion of CD11b-expressing cells in ATRA-
vs vehicle-treated cells was lower in the ARID1B knockdown cells
compared with the control cells. This observation suggests a role
of ARID1B in in vitro differentiation towards the granulocytic
lineage.
Gene expression changes induced by silencing of ARID1B
We performed RNA sequencing of control and ARID1B knockdown
NB4 cells to examine transcriptomic changes caused by suppres-
sion of ARID1B. Gene expression analysis revealed differential
expression of 1028 genes (false discovery rate o0.05). Signifi-
cantly, expression of a majority of genes (740/1028) was elevated
in the ARID1B knockdown cells compared with the control cells,
whereas 288 genes were downregulated (Figure 6a and
Supplementary Figure S13). Gene ontology analysis of upregu-
lated genes showed a marked enrichment for several pathways
related to immune response, signal transduction and hemato-
poietic differentiation, whereas downregulated genes were over-
represented for cell adhesion and WNT signaling (Figure 6b).
Using quantitative real time-PCR, we validated elevated expres-
sion of several genes involved in hematopoietic development and
immune regulation in ARID1B knockdown cells. These included
GATA1, GATA2, IKZF2, NFE2, IRF5, BPI, PRG2 and PRTN3, whereas the
expression of WNT7B and HOXC4 was downregulated (Figure 6c).
In accordance with increased expression of GATA1 and GATA2,
gene set enrichment analysis verified upregulation of their target
genes in ARID1B knockdown NB4 cells (Supplementary
Figure S14).
DISCUSSION
This study provides the most comprehensive profiling of somatic
mutations in APL to date, at both initial diagnosis and relapse. We
demonstrate that the mutational spectrum of APL is notably
different from other AML subtypes. Overall, the topography of
somatic mutations in APL is defined by recurrent alterations of
FLT3,WT1, NRAS, KRAS, ARID1B and ARID1A genes, and the absence
of mutations in other common AML genes incluing DNMT3A,
NPM1, TET2, ASXL1 and IDH1/2. Moreover, the repertoire of
mutations at relapsed APL differs significantly from newly
diagnosed cases and is characterized by alterations in PML and
RARA genes, which are rarely affected by somatic mutations in
primary APL. In our cohort, matched diagnosis samples were
available for three relapse cases (DS4R, DS6R, 243 R) harboring
four PML mutations and one case (29 R) harboring RARA mutation,
all of which were negative for the corresponding mutations of PML
and RARA genes. We also uncovered increased frequency of
ARID1B and RUNX1 mutations in APL relapse. In addition, the
mutational frequency of FLT3 was considerably lower at relapse
compared with primary disease, although the proportion of FLT3-
ITD was similar at the two stages of disease.
APL is distinctive from other AML subclasses in its sensitivity to
ATRA- and ATO-based therapies. In this study, we also examined
relapse-specific mutations in the context of therapeutic interven-
tion used at the initial diagnosis. Notably, our relapse cohort
comprised of sizable number of ATRA-free ATO-treated samples.
We found that the incidence of mutations in RARA and PML genes
largely segregated into post-ATRA and post-ATO relapses,
Figure 5. Silencing of ARID1B impairs ATRA-induced neutrophil differentiation of NB4 cells. (a and b) Generation of NB4 cells with stable
knockdown of ARID1B. Cells transduced with ARID1B shRNA (sh2 or sh3) display significant suppression of ARID1B transcript (two primer
pairs) (a) and protein levels (b) compared with the control transduced (con) cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
transcript levels were used to normalize for RNA in quantitative real time-PCR (qRT-PCR) analysis in (a) and bars represent mean± s.d.
(c) Clonogenic ability of ARID1B knockdown NB4 cells compared with control cells. Cells were plated in methylcellulose media, and colonies
were enumerated after 9 days. Bars represent mean± s.e.m. (d) ATRA-induced differentiation of control and ARID1B knockdown NB4 cells was
determined by surface expression of CD11b. Cells were treated with 0.1, 1 or 10 μM ATRA, and the proportion of CD11b-expressing cells was
determined by flow cytometry at indicated times. The difference in the percentage of CD11b+ cells obtained in ATRA- vs DMSO-treated cells at
each time point is depicted. Data represent mean± s.e.m. of four to five experiments (*Po0.05; Student’s t-test).
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respectively. This indicates distinct mechanisms are involved in
acquisition of resistance following two different therapeutic
regimens.
Our RT-PCR experiments for allele-specific analyses show that
mutations of RARA invariably occurred on the PML-RARA fusion
allele, similar to previous studies.28,45 Mutations of PML occurred in
proximity to the C212-C213 dicysteine residues, which is
associated with binding of ATO to PML moiety.46,47 These
mutations of PML in the B2 domain are associated with resistance
to arsenic therapy.30,32 Although an initial report showed that
mutations of PML in two ATO-resistant cases occurred on the PML-
RARA allele and accounted for an impaired response to therapy,30
we detected mutations of PML either on the rearranged (two
cases) or the wild-type PML allele (one case). A recent report noted
a mutation in the non-rearranged allele of PML gene in a case
which presented with multiple relapses.31 Also, truncating
mutations of wild-type PML allele have been observed in ATRA-
resistant APL,29 indicating that mutations affecting either allele of
PML may have pathological consequences.
Our sequencing data uncover recurrent mutations in two novel
genes, ARID1B and ARID1A, in APL. Somatic mutations in these two
members of SWI/SNF chromatin remodeling complex are very
frequent in gynecologic and several other solid tumors.48–50
However, incidence of somatic alterations in genes of ARID1
family is rare in myeloid leukemia,7,51 although, recently, muta-
tions of ARID1A have been detected in other hematological
malignancies including chronic lymphocytic leukemia, natural
killer/T-cell lymphoma and hairy cell leukemia.52–54 Notably, large
majority of mutations in both ARID1B and ARID1A in APL were
loss-of-function alterations, similar to the truncating mutations
observed in solid tumors.
Germline mutations and chromosomal aberrations affecting
ARID1B are associated with disorders characterized by develop-
mental delay and intellectual disability including Coffin-Siris
syndrome.55,56 Although mutations of ARID1B have been reported
in solid tumors, to our knowledge, this is the first report of ARID1B
alterations in myeloid leukemia. Interestingly, mutations of ARID1B
were more frequent at relapse APL compared with the newly
diagnosed cases in our cohort. Our experiments show that the
knockdown of ARID1B does not significantly modulate either
the cell growth or colony-forming ability in vitro; however, it alters
the differentiation of NB4 cells in response to ATRA. Transcriptome
analysis showed that silencing of ARID1B resulted more promi-
nently in activation of gene expression, suggesting it potentially
functions as a repressor of gene expression.
Several other potentially novel drivers of leukemia were also
identified at low mutational frequencies in this study. Among
them, mutations in the transcription factor CEBPE were observed
in three cases (two primary and one relapse APL), all of which
were potentially deleterious alterations (frameshift insertion/
deletion and splice site mutation). Loss-of-function germline
alteration of CEBPE causes specific granule deficiency, a rare
congenital disorder characterized by neutrophils with abnormal
nuclear morphology, impaired function and lacking secondary and
tertiary granule proteins.57 However, somatic mutations of CEBPE
in myeloid leukemia have not been previously identified. CEBPE is
a critical regulator of granulocytic differentiation and truncating
mutations in this gene may have implications on differentiation of
promyelocytes. Another interesting candidate is a hexokinase
gene, HK3, which was mutated in three APL cases. HK3 is
specifically expressed during granulocytic differentiation and was
previously shown to be downregulated in APL.58 Silencing of HK3
also resulted in impaired ATRA-induced granulocytic differentia-
tion of NB4 cells.58 Four somatic mutations (in three cases) in
NUMA1 gene, located on chromosome 11 and involved in t(11;17)
(q13;q21) translocation to form NUMA1-RARA fusion in variant
cases of APL,59 were also observed. Two primary APL cases
harbored mutations of RUNX1T1, a gene fused with RUNX1 in
Figure 6. Gene expression changes in ARID1B knockdown NB4 cells. (a) Volcano plot depicts differentially expressed genes between ARID1B
knockdown (sh2 and sh3) and control transduced NB4 cells. Horizontal line denotes false discovery rate (FDR)= 0.05. Blue dots represent
genes involved in ‘immune system process’ GO:0002376. (b) Functional enrichment analysis (gene ontology) of genes either upregulated or
downregulated in ARID1B knockdown NB4 cells (FDRo0.05). (c) qRT-PCR analyses of selected genes identified as differentially expressed in
RNA sequencing. GAPDH was used as an endogenous control to normalize for RNA quantity. Bars represent mean± s.e.m.
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AML characterized by t(8;21) translocation. USP9X, an X-linked
intellectual disability gene,60 which encodes for a deubiquitinase
enzyme, was mutated in four APL cases. Although the function of
USP9X in hematopoietic development has not been defined, all
four mutations of USP9X were potentially damaging alterations
(three frameshift deletion and one splice site substitution). The
pathogenic implications of these novel mutations in the devel-
opment of APL remain to be investigated.
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